Gilead (NASDAQ: GILD) CEO sells 15,000 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Gilead Sciences Chairman & CEO Daniel O'Day disclosed open-market sales of 15,000 shares of Common Stock. On July 1, 2026, he sold 3,100 shares at an average price of $127.075 and 11,900 shares at $126.0897, according to the Form 4.
The sales were executed under a Rule 10b5-1 trading plan adopted on February 25, 2026, indicating they were pre-arranged rather than newly timed decisions. Footnotes state sale prices for the reported transactions ranged from $125.59 to $127.44, with full trade-by-trade details available on request.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 15,000 shares ($1,894,400)
Net Sell
2 txns
Insider
O'Day Daniel Patrick
Role
Chairman & CEO
Sold
15,000 shs ($1.89M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 11,900 | $126.0897 | $1.50M |
| Sale | Common Stock | 3,100 | $127.075 | $394K |
Holdings After Transaction:
Common Stock — 610,233 shares (Direct, null)
Footnotes (1)
- The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. Sale prices for the transactions reported range from $125.59 to $126.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Sale prices for the transactions reported range from $126.595 to $127.44. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
Key Figures
Shares sold (total): 15,000 shares
First sale: 3,100 shares at $127.075
Second sale: 11,900 shares at $126.0897
+1 more
4 metrics
Shares sold (total)
15,000 shares
Total open-market sales reported on July 1, 2026
First sale
3,100 shares at $127.075
Common Stock, open-market sale on July 1, 2026
Second sale
11,900 shares at $126.0897
Common Stock, open-market sale on July 1, 2026
Price range
$125.59–$127.44
Footnote range for reported sale prices
Key Terms
Rule 10b5-1 trading plan, open-market sale, Common Stock
3 terms
Rule 10b5-1 trading plan regulatory
"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action: "open-market sale" for each Common Stock transaction."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Common Stock financial
"security_title: "Common Stock" for both non-derivative transactions."
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
What insider transaction did Gilead Sciences (GILD) report for CEO Daniel O'Day?
Gilead Sciences reported that Chairman & CEO Daniel O'Day sold 15,000 shares of Common Stock. The Form 4 shows two open-market sales on July 1, 2026, executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 25, 2026.
What type of transaction is reported for Gilead (GILD) CEO Daniel O'Day?
The Form 4 reports open-market sales of Gilead Common Stock by Daniel O'Day. Both entries use transaction code "S," described as a sale in the open market or private transaction, and are categorized as non-derivative transactions involving the company’s Common Stock.